Christopher Gibson
Director · RECURSION PHARMACEUTICALS, INC.
- 2024
- Jun 5, 2026
- 28
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Christopher Gibson files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Blake Borgeson - $3.38M in RXRX purchases and sales in the last 12 months
- James R. Gibson II - $2.18M in PACB purchases and sales in the last 12 months
- Christian O. Henry - $771K in PACB purchases and sales in the last 12 months
- Oene Mark van - $335K in PACB purchases and sales in the last 12 months
- Najat Khan - $258K in RXRX purchases and sales in the last 12 months
- Robert Hershberg - $125K in RXRX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Christopher Gibson?
Christopher Gibson is a corporate insider, tracked as Director of RECURSION PHARMACEUTICALS, INC. (RXRX). InsiderAlpha holds 28 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Christopher Gibson last file a Form 4?
The most recent primary Form 4 on record is dated 5 June 2026, one of 28 filings going back to 2024.
Has Christopher Gibson been buying or selling stock?
Recorded transactions: 0 open-market purchases and 26 open-market sales ($8.54M) across all tracked filings.
